|Bid||2.9900 x 2200|
|Ask||3.0500 x 4000|
|Day's range||2.9600 - 3.1700|
|52-week range||1.4700 - 15.1200|
|Beta (5Y monthly)||1.36|
|PE ratio (TTM)||N/A|
|Earnings date||07 Nov 2022 - 11 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Analysts working at Wall Street investment banks have some stocks in mind that have fallen on hard times but still have a chance to succeed. Ginkgo Bioworks (NYSE: DNA) and its mission to do fun stuff with DNA excited early investors in 2021. Unfortunately, the company manages custom-built organisms much better than it handles its cash flows.
This call is being webcast live on the events page of the investor section of the Amyris' website at amyris.com. You may listen to a webcast replay of this call by going to the investor section of Amyris' website. With me on today's call are John Melo, president and chief executive officer; and also Eduardo Alvarez, chief operating officer to support our Q&A session today.
Amyris, Inc. (AMRS) delivered earnings and revenue surprises of -50% and 20.06%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?